retatrutide or semaglutide vs. Retatrutide: A Comparison CagriSema vs Retatrutide 2026: Approval

GLP-1 receptor agonist use and colorectal cancer risk in patients with inflammatory bowel disease

For the 9mg dose tested in the TRIUMPH-4 phase 3 trial, 45 units at this concentration hits the target precisely

[1] Advise patients to drink adequate fluids and seek medical review if symptoms persist

More insurance plans are covering FDA-approved medications now than before. If your insurance doesnt cover the injectable pens, some patients may save money by getting medications in vials and using syringes instead

Using GLP-1s for any eating disorders, including anorexia, bulimia or binge eating disorder, is not medically recommended

Ideal candidates typically: Have struggled with weight control despite lifestyle modification Display signs of insulin resistance or metabolic syndrome Require medical assistance to prevent progression of obesity-related diseases Exclusion criteria may include individuals with a history of certain endocrine disorders, pancreatitis, or specific gastrointestinal diseases